Abstract #2445

A novel feature reduction framework for reliable delta-radiomics of prostate cancer response to radiation therapy

Yu-Feng Wang^1,2,3, Sirisha Tadimalla^1,2, Yu Sun¹, Lois Holloway^1,3,4, Niluja Thiruthaneeswaran^2,5, Sandra Turner^2,5, Mark Sidhom⁴, Amy Hayden², Jarad Martin⁶, and Annette Haworth^1,2

¹Institute of Medical Physics, The University of Sydney, Sydney, New South Wales, Australia, ²Sydney West Radiation Oncology, Westmead & Blacktown Hospital, Wentworthville, NSW, Australia, ³Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia, ⁴Liverpool and Macarthur Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW, Australia, ⁵Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia, ⁶Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, NSW, Australia

Synopsis

Keywords: Prostate, Quantitative Imaging, Prostate, radiomics, biomarkers, radiotherapy, treatment response

Motivation: Early detection of recurrent prostate cancer (PCa) following primary radiation therapy (RT) can enable salvage treatments. Delta-radiomics from longitudinal quantitative MRI shows promise as treatment response imaging biomarkers.

Goal(s): To develop a framework for identifying reliable radiomic features for robust, early detection of response to RT in PCa.

Approach: Voxel-wise radiomic feature maps were extracted from longitudinal quantitative MRI and assessed for their ability to detect treatment-related changes, accounting for measurement uncertainties.

Results: Only 20% of features with significant post-RT changes were reliably detectable. This framework can identify features that may improve predictive models for treatment response monitoring.

Impact: A framework for identifying reliable features in delta-radiomics of longitudinal prostate qMRI was developed. Predictive models built with these robust radiomic features may enable early detection and localisation of recurrences, providing an opportunity for salvage therapies of treatment-resistant tumours.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.